Kogure Y - Search Results

1

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).

Fukui T, Sasaki J, Igawa S, Kada A, Saito TI, Kogure Y, Okamoto H, Naoki K. Fukui T, et al. Among authors: kogure y. BMC Cancer. 2022 Dec 15;22(1):1314. doi: 10.1186/s12885-022-10409-6. BMC Cancer. 2022. PMID: 36522630 Free PMC article.

2

Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.

Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. Kogure Y, et al. J Thorac Oncol. 2013 Jun;8(6):753-8. doi: 10.1097/JTO.0b013e31828b51f5. J Thorac Oncol. 2013. PMID: 23575412 Free article.

3

Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens.

Oki M, Yatabe Y, Saka H, Kitagawa C, Kogure Y, Ichihara S, Moritani S. Oki M, et al. Among authors: kogure y. Respiration. 2015;89(3):235-42. doi: 10.1159/000369860. Epub 2015 Feb 11. Respiration. 2015. PMID: 25676841 Free article.

4

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.

Kogure Y, Saka H, Oki M, Saito TI, Ahmed SN, Kitagawa C, Imaizumi K. Kogure Y, et al. PLoS One. 2015 Aug 11;10(8):e0135393. doi: 10.1371/journal.pone.0135393. eCollection 2015. PLoS One. 2015. PMID: 26262682 Free PMC article.

5

Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.

Kimura T, Taniguchi H, Watanabe N, Saka H, Kogure Y, Shindo J, Ogasawara T, Kojima E, Hasegawa Y, Yamamoto M, Suzuki R, Ando M, Kondo M, Saito H. Kimura T, et al. Among authors: kogure y. Anticancer Res. 2016 Apr;36(4):1767-71. Anticancer Res. 2016. PMID: 27069157 Clinical Trial.

6

[Association between Efficacy of Pemetrexed and EGFR Mutation Status for EGFR Mutated Lung Carcinoma].

Kogure Y, Saka H, Imaizumi K. Kogure Y, et al. Gan To Kagaku Ryoho. 2016 Jun;43(6):733-5. Gan To Kagaku Ryoho. 2016. PMID: 27306810 Japanese.

7

A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.

Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y. Kogure Y, et al. Clin Lung Cancer. 2018 Sep;19(5):e711-e715. doi: 10.1016/j.cllc.2018.05.005. Epub 2018 May 19. Clin Lung Cancer. 2018. PMID: 29861395 Clinical Trial.

8

[Cost Effectiveness and Health Economics of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer].

Kogure Y. Kogure Y. Gan To Kagaku Ryoho. 2018 May;45(5):781-784. Gan To Kagaku Ryoho. 2018. PMID: 30026436 Japanese.

9

T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring EGFR Mutations.

Kogure Y, Shigematsu F, Oki M, Saka H. Kogure Y, et al. In Vivo. 2018 Sep-Oct;32(5):1199-1204. doi: 10.21873/invivo.11364. In Vivo. 2018. PMID: 30150444 Free PMC article.

10

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer.

Yoshioka H, Kogure Y, Ando M, Kitagawa C, Iwasaku M, Niwa T, Saka H. Yoshioka H, et al. Among authors: kogure y. In Vivo. 2018 Nov-Dec;32(6):1581-1586. doi: 10.21873/invivo.11417. In Vivo. 2018. PMID: 30348719 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page